<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36761395</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1176-6328</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Neuropsychiatric disease and treatment</Title><ISOAbbreviation>Neuropsychiatr Dis Treat</ISOAbbreviation></Journal><ArticleTitle>Neurological Manifestations of Long COVID: A Single-Center One-Year Experience.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>319</EndPage><MedlinePgn>311-319</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/NDT.S387501</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">We report our single-center experience on the neurological manifestations of long COVID.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">This is a retrospective observational study. All consecutive patients referred to the neurological long COVID outpatient clinic of our institute from January 21 2021 to December 9 2021 underwent a general neurological objective examination. Treatments and investigations (brain MRI, neuropsychological evaluation, or others) were prescribed on an individual basis as per standard clinical practice. A follow-up visit was performed when appropriate. Descriptive statistics were presented as absolute and relative frequencies for categorical variables and as means, median, and ranges for continuous variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">One hundred and three patients were visited (mean age 50.5 &#xb1;36 years, 62 females). The average time from acute COVID-19 infection to the first visit to our outpatient clinic was 243 days. Most patients presented with a mild form of acute COVID-19, with only 24 cases requiring hospitalization. The neurological symptoms mostly (n=70/103, 68%) started during the acute phase (before a negative swab for SARS-CoV-2). The most frequent acute manifestations reported, which lately became persistent, were fatigue (n=58/103, 56%), olfactory/taste dysfunction (n=58/103, 56%), headache (n=47/103, 46%), cognitive disorders (n=46/103, 45%), sleep disorders (n=30/103, 29%), sensitivity alterations (n=29/103, 28%), and dizziness (n=7/103, 7%). Tremor was also reported (n=8/103, 7%). Neuropsychological evaluation was performed in 30 patients and revealed alterations in executive functions (n=6/30, 20%), memory (n=11/30, 37%), with pathological depressive (n=9/30, 30%) and anxiety (n=8/30, 27%) scores. Brain MRIs have been performed in 41 cases, revealing nonspecific abnormal findings only in 4 cases. Thirty-six patients underwent a follow-up, where a general improvement was observed but rarely (n=2/36) a complete recovery.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The majority of patients presenting persistent neurological symptoms (most frequently fatigue, cognitive disorders, and olfactory dysfunctions) developed a previous mild form of COVID-19. Further studies are required to develop therapeutic strategies.</AbstractText><CopyrightInformation>&#xa9; 2023 Taruffi et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Taruffi</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Muccioli</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitolo</LastName><ForeName>Micaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Descovich</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Governance, Research, Education and Quality Improvement Unit, AUSL Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzoni</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michelucci</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lodi</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liguori</LastName><ForeName>Rocco</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1815-1013</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortelli</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonon</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bisulli</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1109-7296</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Neuropsychiatr Dis Treat</MedlineTA><NlmUniqueID>101240304</NlmUniqueID><ISSNLinking>1176-6328</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID 19</Keyword><Keyword MajorTopicYN="N">cognitive disorders</Keyword><Keyword MajorTopicYN="N">follow-up</Keyword><Keyword MajorTopicYN="N">hypo/anosmia</Keyword><Keyword MajorTopicYN="N">neuroCOVID</Keyword><Keyword MajorTopicYN="N">neuropsychology</Keyword></KeywordList><CoiStatement>Prof. Dr. Rocco Liguori reports personal fees from SUMMEET s.r.l., ALEXION PHARMA ITALY s.r.l., UCB PHARMA S.p.A., ARGENX BV, AMICUS THERAPEUTICS s.r.l., EDITREE s.r.l., outside the submitted work. The authors report no other conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>3</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36761395</ArticleId><ArticleId IdType="pmc">PMC9904212</ArticleId><ArticleId IdType="doi">10.2147/NDT.S387501</ArticleId><ArticleId IdType="pii">387501</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sivan M, Taylor S. NICE guideline on long covid. BMJ. 2020;m4938. doi:10.1136/bmj.m4938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi:10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;n136. doi:10.1136/bmj.n136</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159&#x2013;167. doi:10.1093/fampra/cmab076</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensato U, Muccioli L, Cani I, et al. Brain dysfunction in COVID&#x2010;19 and CAR&#x2010;T therapy: cytokine storm&#x2010;associated encephalopathy. Ann Clin Transl Neurol. 2021;8(4):968&#x2013;979. doi:10.1002/acn3.51348</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51348</ArticleId><ArticleId IdType="pmc">PMC8045903</ArticleId><ArticleId IdType="pubmed">33780166</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375(6578):267&#x2013;269. doi:10.1126/science.abm2052</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Rass V, Beer R, Schiefecker AJ, et al. Neurological outcomes 1 year after COVID-19 diagnosis: a prospective longitudinal cohort study. Eur J Neurol. 2022;29(6):1685&#x2013;1696. doi:10.1111/ene.15307</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15307</ArticleId><ArticleId IdType="pmc">PMC9111823</ArticleId><ArticleId IdType="pubmed">35239247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network &#x2014; United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993&#x2013;998. doi:10.15585/mmwr.mm6930e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bockman CS, Eckerson J, McCarson KE. Myalgia. Reference Module Biomed Sci. 2015;B9780128012383052000. doi:10.1016/B978-0-12-801238-3.05161-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-801238-3.05161-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Enoka RM. Fatigue. Larry R, ed:Squire, Encyclopedia of Neuroscience, Academic Press: 2009. 201&#x2013;206.</Citation></Reference><Reference><Citation>Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S. &#x201c;Sniffin&#x2019; sticks&#x201d;: screening of olfactory performance. Rhinology. 1996;34(4):222&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">9050101</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta-Rodolfi C, Gasparini F, Ghidoni E. Kit del neuropsicologo italiano. Bologna Soc Ital Neuropsicol. 2011;1:498.</Citation></Reference><Reference><Citation>Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995;33(3):335&#x2013;343. doi:10.1016/0005-7967(94)00075-U</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-7967(94)00075-U</ArticleId><ArticleId IdType="pubmed">7726811</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson RD. Psychometric properties of the modified fatigue impact scale. Int J MS Care. 2013;15(1):15&#x2013;20. doi:10.7224/1537-2073.2012-019</Citation><ArticleIdList><ArticleId IdType="doi">10.7224/1537-2073.2012-019</ArticleId><ArticleId IdType="pmc">PMC3883028</ArticleId><ArticleId IdType="pubmed">24453758</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2(1):e13&#x2013;e22. doi:10.1016/S2666-5247(20)30172-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017&#x2013;1032. doi:10.1038/s41591-020-0968-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xydakis MS, Albers MW, Holbrook EH, et al. Post-viral effects of COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021;20(9):753&#x2013;761. doi:10.1016/S1474-4422(21)00182-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00182-4</ArticleId><ArticleId IdType="pmc">PMC8324113</ArticleId><ArticleId IdType="pubmed">34339626</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou MI, Palaiodimou L, Bakola E, et al. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis. 2022;13:20406223221076890. doi:10.1177/20406223221076890</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221076890</ArticleId><ArticleId IdType="pmc">PMC8859684</ArticleId><ArticleId IdType="pubmed">35198136</ArticleId></ArticleIdList></Reference><Reference><Citation>Callan C, Ladds E, Husain L, Pattinson K, Greenhalgh T. &#x2018;I can&#x2019;t cope with multiple inputs&#x2019;: a qualitative study of the lived experience of &#x2018;brain fog&#x2019; after COVID-19. BMJ Open. 2022;12(2):e056366. doi:10.1136/bmjopen-2021-056366</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-056366</ArticleId><ArticleId IdType="pmc">PMC8844964</ArticleId><ArticleId IdType="pubmed">35149572</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Cristillo V, Cotti Piccinelli S, et al. Long-term neurological manifestations of COVID-19: prevalence and predictive factors. Neurol Sci. 2021;42(12):4903&#x2013;4907. doi:10.1007/s10072-021-05586-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05586-4</ArticleId><ArticleId IdType="pmc">PMC8439956</ArticleId><ArticleId IdType="pubmed">34523082</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil. 2022;101(1):48&#x2013;52. doi:10.1097/PHM.0000000000001910</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CJ, Renshaw P, Yurgelun-Todd D, Sheth C. Acute and chronic neuropsychiatric symptoms in novel coronavirus disease 2019 (COVID-19) patients: a qualitative review. Front Public Health. 2022;10:772335. doi:10.3389/fpubh.2022.772335</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.772335</ArticleId><ArticleId IdType="pmc">PMC9404694</ArticleId><ArticleId IdType="pubmed">36033820</ArticleId></ArticleIdList></Reference><Reference><Citation>Katal S, Balakrishnan S, Gholamrezanezhad A. Neuroimaging and neurologic findings in COVID-19 and other coronavirus infections: a systematic review in 116 patients. J Neuroradiol J Neuroradiol. 2021;48(1):43&#x2013;50. doi:10.1016/j.neurad.2020.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurad.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7320684</ArticleId><ArticleId IdType="pubmed">32603770</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Randomized clinical trial &#x201c;olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin&#x201d;: preliminary results. Eur Rev Med Pharmacol Sci. 2021;25(11):4156&#x2013;4162. doi:10.26355/eurrev_202106_26059</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202106_26059</ArticleId><ArticleId IdType="pubmed">34156697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>